Key facts
- Notable investors include Tenity, NLC Health Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Genorare
- ·The full record, as it builds
Funding rounds
No funding rounds for Genorare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genorare
Developer of an AI-powered rare disease diagnosis platform designed to accelerate and secure the diagnostic process for rare diseases. The company's platform combines artificial intelligence, including large language models and predictive analytics to offer real-time diagnosis support, clinical trial matching and patient-doctor matching, enabling clinicians and researchers to achieve faster, accurate, and secure diagnostic insights for rare diseases.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2025
- Employees
- 3
- Website
- genorare.com/
- Ownership
- Privately Held (backing)
Genorare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genorare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genorare in its N-PORT filings yet. We sweep new filings monthly.